卵巢癌的免疫治疗。
Immunotherapy in ovarian cancer.
机构信息
Division of Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Hum Vaccin Immunother. 2012 Sep;8(9):1179-91. doi: 10.4161/hv.20738. Epub 2012 Aug 21.
Abstract
Ovarian cancer is the most deadly gynecologic malignancy, with more than 15,000 deaths anticipated in 2012. While approximately 80% of patients will respond to frontline chemotherapy, more than 60% of patients will experience disease recurrence and only 44% will be alive at 5 y. Host anti-tumor immune responses are associated with a significant improvement in overall survival for women with ovarian cancer. By bolstering these responses, it may therefore be possible to significantly influence the prognosis of women with this lethal disease. In this review, we will focus on innovative immune-based strategies which are currently being investigated in the treatment of ovarian cancer.
摘要
卵巢癌是最致命的妇科恶性肿瘤，预计 2012 年将有超过 15000 人死亡。虽然大约 80%的患者对一线化疗有反应，但超过 60%的患者会出现疾病复发，只有 44%的患者在 5 年内存活。宿主抗肿瘤免疫反应与卵巢癌患者总体生存率的显著提高相关。因此，通过增强这些反应，可能会显著影响患有这种致命疾病的女性的预后。在这篇综述中，我们将重点介绍目前正在研究用于治疗卵巢癌的创新免疫策略。
相似文献
1
Immunotherapy in ovarian cancer.
Hum Vaccin Immunother. 2012 Sep;8(9):1179-91. doi: 10.4161/hv.20738. Epub 2012 Aug 21.
2
Preface.
Cancer Metastasis Rev. 2015 Mar;34(1):3. doi: 10.1007/s10555-014-9548-7.
3
Immunotherapy in ovarian cancer.
Curr Probl Cancer. 2017 Jan-Feb;41(1):48-63. doi: 10.1016/j.currproblcancer.2016.11.003. Epub 2016 Nov 15.
4
Targeted immune therapy of ovarian cancer.
Cancer Metastasis Rev. 2015 Mar;34(1):53-74. doi: 10.1007/s10555-014-9540-2.
5
Immunity and immune suppression in human ovarian cancer.
Immunotherapy. 2011 Apr;3(4):539-56. doi: 10.2217/imt.11.20.
6
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
J Immunol Res. 2015;2015:191832. doi: 10.1155/2015/191832. Epub 2015 Jul 7.
7
The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).
Int J Oncol. 2008 Jun;32(6):1145-57. doi: 10.3892/ijo_32_6_1145.
8
Immunotherapy in Ovarian Cancer.
Surg Oncol Clin N Am. 2019 Jul;28(3):447-464. doi: 10.1016/j.soc.2019.02.002. Epub 2019 Apr 5.
9
Immunotherapy opportunities in ovarian cancer.
Expert Rev Anticancer Ther. 2008 Feb;8(2):243-57. doi: 10.1586/14737140.8.2.243.
10
Immunotherapy for ovarian cancer: recent advances and perspectives.
Curr Opin Oncol. 2014 Sep;26(5):492-500. doi: 10.1097/CCO.0000000000000111.
引用本文的文献
1
Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates.
NPJ Vaccines. 2025 Aug 16;10(1):195. doi: 10.1038/s41541-025-01234-6.
2
First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer.
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf115.
3
Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer.
J Immunol Res. 2024 Jun 12;2024:4312908. doi: 10.1155/2024/4312908. eCollection 2024.
4
Adipocyte pyroptosis occurs in omental tumor microenvironment and is associated with chemoresistance of ovarian cancer.
J Biomed Sci. 2024 Jun 11;31(1):62. doi: 10.1186/s12929-024-01051-4.
5
Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer.
Int J Mol Sci. 2024 Mar 9;25(6):3173. doi: 10.3390/ijms25063173.
6
The Prognosis Predictive Score around Neo Adjuvant Chemotherapy (PPSN) Improves Diagnostic Efficacy in Predicting the Prognosis of Epithelial Ovarian Cancer Patients.
Cancers (Basel). 2023 Oct 19;15(20):5062. doi: 10.3390/cancers15205062.
7
Establishing Molecular Subgroups of CD8+ T Cell-Associated Genes in the Ovarian Cancer Tumour Microenvironment and Predicting the Immunotherapy Response.
Biomedicines. 2023 Aug 28;11(9):2399. doi: 10.3390/biomedicines11092399.
8
Cancer-mesothelial and cancer-macrophage interactions in the ovarian cancer microenvironment.
Am J Physiol Cell Physiol. 2023 Sep 1;325(3):C721-C730. doi: 10.1152/ajpcell.00461.2022. Epub 2023 Aug 7.
9
Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens.
Int J Mol Sci. 2023 Jan 24;24(3):2292. doi: 10.3390/ijms24032292.
10
Exosome-Associated Gene Signature for Predicting the Prognosis of Ovarian Cancer Patients.
J Immunol Res. 2023 Jan 23;2023:8727884. doi: 10.1155/2023/8727884. eCollection 2023.
本文引用的文献
1
Cancer statistics, 2012.
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
2
A phase 3 trial of bevacizumab in ovarian cancer.
N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799.
3
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390.
4
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.
Int J Cancer. 2012 Sep 1;131(5):E670-80. doi: 10.1002/ijc.27388. Epub 2012 Jan 31.
5
Cancer immunotherapy comes of age.
J Clin Oncol. 2011 Dec 20;29(36):4828-36. doi: 10.1200/JCO.2011.38.0899. Epub 2011 Oct 31.
6
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.
Gynecol Oncol. 2012 Feb;124(2):192-8. doi: 10.1016/j.ygyno.2011.09.039. Epub 2011 Oct 29.
7
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.
Cancer Immunol Immunother. 2012 May;61(5):629-41. doi: 10.1007/s00262-011-1081-8. Epub 2011 Oct 22.
8
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
Cancer Immunol Immunother. 2012 Mar;61(3):373-84. doi: 10.1007/s00262-011-1100-9. Epub 2011 Sep 17.
9
WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
Anticancer Res. 2011 Jul;31(7):2441-5.
10
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group.
Gynecol Oncol. 2011 Oct;123(1):27-32. doi: 10.1016/j.ygyno.2011.06.004. Epub 2011 Jul 5.
Zotero 插件